The effect of midazolam drug on the occurrence of restlessness and agitation in patients undergoing electroshock therapy

Investigating the effect of midazolam on the incidence of restlessness and agitation in patients undergoing electroshock therapy at 5 Azar Hospital in Gorgan in 2023

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170108031818N3

Enrollment

100

Registered

2023-01-23

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing electroshock therapy.

Interventions

Intervention 1: For the intervention group, before the induction of anesthesia, hemodynamic symptoms are measured before anesthesia, and the patient is preoxygenated. Then midazolam drug at the rate o

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The patient diagnosed with psychosis is indicated for ECT

Exclusion criteria

Exclusion criteria: Age range 18-75 years Patient satisfaction to conduct research

Design outcomes

Primary

Measure	Time frame
Restlessness and agitation. Timepoint: Twice a day at 8-10 and 16-18 for a maximum of 4 days. Method of measurement: The Richmond Agitation and Sedation Scale (RASS).	—

Secondary

Measure	Time frame
Cardiovascular response of trauma patients in special surgery departments. Timepoint: Before and after each drug intervention. Method of measurement: Blood pressure with a blood pressure monitor device and the patient's pulse with a heart and breathing monitor with a manual counter in one minute.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyed Maherukh Madah

Gorgan University of Medical Sciences

mehravar10261@yahoo.com+98 17 3217 7419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026